Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone.
Adolescent
Adult
Aged
B7-H1 Antigen
/ genetics
Biomarkers, Tumor
/ genetics
Bone Neoplasms
/ genetics
Bone and Bones
/ pathology
Down-Regulation
/ genetics
Female
Giant Cell Tumors
/ genetics
Humans
Immune Tolerance
/ genetics
Male
Middle Aged
Neoplasm Recurrence, Local
/ genetics
Prognosis
Transcriptome
/ immunology
Up-Regulation
/ genetics
Young Adult
Giant cell tumor of bone
Immune-related genes
NanoString technology
PD-L1
Prognosis
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
19
08
2019
accepted:
27
04
2020
pubmed:
8
5
2020
medline:
18
8
2020
entrez:
8
5
2020
Statut:
ppublish
Résumé
Giant cell tumor of bone (GCTB) is a locally aggressive and rarely metastatic tumor, with a relatively unpredictable clinical course. A retrospective series of 46 GCTB and a control group of 24 aneurysmal bone cysts (ABC) were selected with the aim of investigating the PD-L1 expression levels and immune-related gene expression profile, in correlation with clinicopathological features. PD-L1 and Ki67 were immunohistochemically tested in each case. Furthermore, comprehensive molecular analyses were carried out using NanoString technology and nCounter PanCancer Immune Profiling Panel, and the gene expression results were correlated with clinicopathological characteristics. PD-L1 expression was observed in 13/46 (28.3%) GCTB (and in 1/24, 4.2%, control ABC, only) and associated with a shorter disease free interval according to univariate analysis. Moreover, in PD-L1-positive lesions, three genes (CD27, CD6 and IL10) were significantly upregulated (p < 0.01), while two were downregulated (LCK and TLR8, showing borderline significance, p = 0.06). Interestingly, these genes can be related to maturation and immune tolerance of bone tissue microenvironment, suggesting a more immature/anergic phenotype of giant cell tumors. Our findings suggest that PD-L1 immunoreactivity may help to select GCTB patients with a higher risk of recurrence who could potentially benefit from immune checkpoint blockade.
Identifiants
pubmed: 32377818
doi: 10.1007/s00262-020-02594-9
pii: 10.1007/s00262-020-02594-9
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1905-1916Subventions
Organisme : Fondazione per i Tumori muscolo scheletrici
ID : 1704/2018
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca-MIUR
ID : D15D18000410001
Références
Cowan RW, Singh G (2013) Giant cell tumor of bone: a basic science perspective. Bone 52:238–246. https://doi.org/10.1016/j.bone.2012.10.002
doi: 10.1016/j.bone.2012.10.002
pubmed: 23063845
Athanasou NA, Bansal M, Forsyth R, Reid RP, Sapi Z (2013) Giant cell tumour of bone. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F (eds) WHO classification of tumours of soft tissue and bone, 4th edn. IARC Press, Lyon, pp 321–324
Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S, Rimondi E et al (2010) Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 36:1–7. https://doi.org/10.1016/j.ctrv.2009.09.002
doi: 10.1016/j.ctrv.2009.09.002
pubmed: 19879054
Werner M (2006) Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthop 30:484–489. https://doi.org/10.1007/s00264-006-0215-7
doi: 10.1007/s00264-006-0215-7
pubmed: 17013643
pmcid: 3172738
Luo G, Li F, Li X, Wang ZG, Zhang B (2018) TNF-α and RANKL promote osteoclastogenesis by upregulating RANK via the NF-κB pathway. Mol Med Rep 17:6605–6611. https://doi.org/10.3892/mmr.2018.8698
doi: 10.3892/mmr.2018.8698
pubmed: 29512766
pmcid: 5928634
Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S, Bouralexis S, Findlay DM (2000) Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 15:640–649. https://doi.org/10.1359/jbmr.2000.15.4.640
doi: 10.1359/jbmr.2000.15.4.640
pubmed: 10780856
Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342. https://doi.org/10.1038/nature01658
doi: 10.1038/nature01658
pubmed: 12748652
Maros ME, Schnaidt S, Balla P, Kelemen Z, Sapi Z et al (2019) In situ cell cycle analysis in giant cell tumor of bone reveals patients with elevated risk of reduced progression-free survival. Bone 127:188–198. https://doi.org/10.1016/j.bone.2019.06.022
doi: 10.1016/j.bone.2019.06.022
pubmed: 31233932
Kervarrec T, Collin C, Larousserie F, Bouvier C, Aubert S, Gomez-Brouchet A et al (2017) H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach. Mod Pathol 30:393–406. https://doi.org/10.1038/modpathol.2016.212
doi: 10.1038/modpathol.2016.212
pubmed: 28059095
Righi A, Mancini I, Gambarotti M, Picci P, Gamberi G, Marraccini C et al (2017) Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone. Hum Pathol 68:128–135. https://doi.org/10.1016/j.humpath.2017.08.033
doi: 10.1016/j.humpath.2017.08.033
pubmed: 28899740
Lüke J, von Baer A, Schreiber J, Lübbehüsen C, Breining T, Mellert K et al (2017) H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology 71:125–133. https://doi.org/10.1111/his.13190
doi: 10.1111/his.13190
pubmed: 28211081
Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ et al (2015) Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res 1:113–123. https://doi.org/10.1002/cjp2.13
doi: 10.1002/cjp2.13
pubmed: 27499898
pmcid: 4858131
Montgomery C, Couch C, Emory CL, Nicholas R (2019) Giant cell tumor of bone: review of current literature, evaluation, and treatment options. J Knee Surg 32:331–336. https://doi.org/10.1055/s-0038-1675815
doi: 10.1055/s-0038-1675815
pubmed: 30449024
Chen L, Ding XY, Wang CS, Si MJ, Du LJ, Zhang WB, Lu Y (2014) In-depth analysis of local recurrence of giant cell tumour of bone with soft tissue extension after intralesional curettage. Radiol Med 119:861–870. https://doi.org/10.1007/s11547-014-0396-x
doi: 10.1007/s11547-014-0396-x
pubmed: 24604549
Errani C, Tsukamoto S, Leone G, Akahane M, Cevolani L, Tanzi P et al (2017) Higher local recurrence rates after intralesional surgery for giant cell tumor of the proximal femur compared to other sites. Eur J Orthop Surg Traumatol 27:813–819. https://doi.org/10.2106/JBJS.17.00057
doi: 10.2106/JBJS.17.00057
pubmed: 28589498
Lausten GS, Jensen PK, Schiødt T, Lund B (1996) Local recurrences in giant cell tumour of bone. Long-term follow up of 31 cases. Int Orthop 20:172–176. https://doi.org/10.1007/s002640050057
doi: 10.1007/s002640050057
pubmed: 8832321
Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM et al (2012) Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 18:4415–4424. https://doi.org/10.1158/1078-0432.CCR-12-0578
doi: 10.1158/1078-0432.CCR-12-0578
pubmed: 22711702
Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J (2019) Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg. https://doi.org/10.1007/s00402-019-03167-x
doi: 10.1007/s00402-019-03167-x
pubmed: 30877429
Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S et al (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 14:901–908. https://doi.org/10.1016/S1470-2045(13)70277-8
doi: 10.1016/S1470-2045(13)70277-8
pubmed: 23867211
Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, Donati DM (2018) Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am 100:496–504. https://doi.org/10.2106/JBJS.17.00057
doi: 10.2106/JBJS.17.00057
pubmed: 29557866
van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H (2017) Giant cell tumour of bone in the denosumab era. Eur J Cancer 77:75–83. https://doi.org/10.1016/j.ejca.2017.02.021
doi: 10.1016/j.ejca.2017.02.021
pubmed: 28365529
Errani C, Tsukamoto S, Mavrogenis AF (2017) How safe and effective is denosumab for bone giant cell tumour? Int Orthop 41:2397–2400. https://doi.org/10.1007/s00264-017-3536-9
doi: 10.1007/s00264-017-3536-9
pubmed: 28646421
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
Domingues B, Lopes JM, Soares P, Pópulo H (2018) Melanoma treatment in review. Immunotargets Ther 7:35–49. https://doi.org/10.2147/ITT.S134842
doi: 10.2147/ITT.S134842
pubmed: 29922629
pmcid: 5995433
Yu Y, Cui J (2018) Present and future of cancer immunotherapy: a tumor microenvironmental perspective. Oncol Lett 16:4105–4113. https://doi.org/10.3892/ol.2018.9219
doi: 10.3892/ol.2018.9219
pubmed: 30214551
pmcid: 6126324
Wang Z, Wang Z, Li B, Wang S, Chen T, Ye Z (2019) Innate immune cells: a potential and promising cell population for treating osteosarcoma. Front Immunol 10:1114. https://doi.org/10.3389/fimmu.2019.01114
doi: 10.3389/fimmu.2019.01114
pubmed: 6531991
pmcid: 6531991
Uehara T, Fujiwara T, Takeda K, Kunisada T, Ozaki T, Udono H (2015) Immunotherapy for bone and soft tissue sarcomas. Biomed Res Int 2015:820813. https://doi.org/10.1155/2015/820813
doi: 10.1155/2015/820813
pubmed: 26167500
pmcid: 4488089
Zheng W, Xiao H, Liu H, Zhou Y (2015) Expression of programmed death 1 is correlated with progression of osteosarcoma. APMIS 123:102–107. https://doi.org/10.1111/apm.12311
doi: 10.1111/apm.12311
pubmed: 25257510
Torabi A, Amaya CN, Wians FH Jr, Bryan BA (2017) PD-1 and PD-L1 expression in bone and soft tissue sarcomas. Pathology 49:506–513. https://doi.org/10.1016/j.pathol.2017.05.003
doi: 10.1016/j.pathol.2017.05.003
pubmed: 28688724
McEachron TA, Triche TJ, Sorenson L, Parham DM, Carpten JD (2018) Profiling targetable immune checkpoints in osteosarcoma. Oncoimmunology 7:e1475873. https://doi.org/10.1080/2162402X.2018.1475873
doi: 10.1080/2162402X.2018.1475873
pubmed: 30524885
pmcid: 6279416
Wang J, Hu C, Wang J, Shen Y, Bao Q, He F et al (2019) Checkpoint blockade in combination with doxorubicin augments tumor cell apoptosis in osteosarcoma. J Immunother. https://doi.org/10.1097/CJI.0000000000000281
doi: 10.1097/CJI.0000000000000281
pubmed: 31478975
pmcid: 7077957
Rehkämper J, Steinestel K, Jeiler B, Elges S, Hekeler E, Huss S et al (2018) Diagnostic tools in the differential diagnosis of giant cell-rich lesions of bone at biopsy. Oncotarget 9:30106–30114. https://doi.org/10.18632/oncotarget.25725
doi: 10.18632/oncotarget.25725
pubmed: 30046391
pmcid: 6059026
Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M et al (2018) Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study. World J Surg Oncol 16:160. https://doi.org/10.1186/s12957-018-1459-6
doi: 10.1186/s12957-018-1459-6
pubmed: 30089488
pmcid: 6083623
Yoshida K, Okamoto M, Sasaki J, Kuroda C, Ishida H, Ueda K et al (2019) Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers. Onco Targets Ther 12:2513–2518. https://doi.org/10.2147/OTT.S198421
doi: 10.2147/OTT.S198421
pubmed: 31040694
pmcid: 6452806
Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM et al (2013) Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 8:e82870. https://doi.org/10.1371/journal.pone.0082870
doi: 10.1371/journal.pone.0082870
pubmed: 24349382
pmcid: 3859621
Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH et al (2016) Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer 16:434. https://doi.org/10.1186/s12885-016-2451-6
doi: 10.1186/s12885-016-2451-6
pubmed: 27393385
pmcid: 4938996
Xiao Y, Song JY, de Vries TJ, Fatmawati C, Parreira DB, Langenbach GE et al (2013) Osteoclast precursors in murine bone marrow express CD27 and are impeded in osteoclast development by CD70 on activated immune cells. Proc Natl Acad Sci USA 110:12385–12390. https://doi.org/10.1073/pnas.1216082110
doi: 10.1073/pnas.1216082110
pubmed: 23832783
Bozec A, Zaiss MM (2017) T regulatory cells in bone remodelling. Curr Osteoporos Rep 15:121–125. https://doi.org/10.1007/s11914-017-0356-1
doi: 10.1007/s11914-017-0356-1
pubmed: 28432597
Oliveira MI, Gonçalves CM, Pinto M, Fabre S, Santos AM, Lee SF et al (2012) CD6 attenuates early and late signaling events, setting thresholds for T-cell activation. Eur J Immunol 42:195–205. https://doi.org/10.1002/eji.201040528
doi: 10.1002/eji.201040528
pubmed: 21956609
Kato I, Furuya M, Matsuo K, Kawabata Y, Tanaka R, Ohashi K (2018) Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses. Histopathology 72:914–922. https://doi.org/10.1111/his.13448
doi: 10.1111/his.13448
pubmed: 29206281
Solari F, Domenget C, Gire V, Woods C, Lazarides E, Rousset B, Jurdic P (1995) Multinucleated cells can continuously generate mononucleated cells in the absence of mitosis: a study of cells of the avian osteoclast lineage. J Cell Sci 108:3233–3241
pubmed: 7593284
Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z et al (2016) Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis 5:e281. https://doi.org/10.1038/oncsis.2016.75
doi: 10.1038/oncsis.2016.75
pubmed: 27991913
pmcid: 5177773
Janssens S, Beyaert R (2003) Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 16:637–646. https://doi.org/10.1128/CMR.16.4.637-646.2003
doi: 10.1128/CMR.16.4.637-646.2003
pubmed: 14557290
pmcid: 14557290
Schmiedel BJ, Grosse-Hovest L, Salih HR (2013) A “vicious cycle” of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL? Oncoimmunology 2:e23850. https://doi.org/10.4161/onci.23850
doi: 10.4161/onci.23850
pubmed: 23762785
pmcid: 3667891
Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC et al (2006) Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 18:1115–1126. https://doi.org/10.1093/intimm/dxl046
doi: 10.1093/intimm/dxl046
pubmed: 16728430
Huang L, Zhu P, Xia P, Fan Z (2016) WASH has a critical role in NK cell cytotoxicity through Lck-mediated phosphorylation. Cell Death Dis 7:e2301. https://doi.org/10.1038/cddis.2016.212
doi: 10.1038/cddis.2016.212
pubmed: 27441653
pmcid: 4973352
Francisconi CF, Vieira AE, Azevedo MCS, Tabanez AP, Fonseca AC, Trombone APF et al (2018) RANKL triggers treg-mediated immunoregulation in inflammatory osteolysis. J Dent Res 97:917–927. https://doi.org/10.1177/0022034518759302
doi: 10.1177/0022034518759302
pubmed: 29499125
pmcid: 6728554
Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E et al (2017) Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer 76:118–124. https://doi.org/10.1016/j.ejca.2017.01.028
doi: 10.1016/j.ejca.2017.01.028
pubmed: 28324746
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al (2017) IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930–2940. https://doi.org/10.1172/JCI91190
doi: 10.1172/JCI91190
pubmed: 28650338
pmcid: 5531419
Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I et al (2018) Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer 6:63. https://doi.org/10.1186/s40425-018-0367-1
doi: 10.1186/s40425-018-0367-1
pubmed: 29929551
pmcid: 6013904
Klein S, Mauch C, Wagener-Ryczek S, Schoemmel M, Buettner R, Quaas A et al (2019) Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. Cancer Immunol Immunother 68:973–982. https://doi.org/10.1007/s00262-019-02339-3
doi: 10.1007/s00262-019-02339-3
pubmed: 30963193